Martin Mackay, Alexion Pharmaceuticals

2014 pay package: $6.8 million
2013 pay package: $6.3 million
Change: +7.9%
2014 compensation: $650,000 in salary, $690,000 in nonequity incentive pay; $2.7 million in stock awards; $2.7 million worth of options; and $23,000 in other compensation

Deposed from AstraZeneca ($AZN) in 2013, Martin Mackay has adjusted well to life outside of Big Pharma, taking home another big paycheck as head of research at the company behind the world's most expensive drug.

In his first full year at Alexion Pharmaceuticals ($ALXN), Mackay saw his incentive pay jump by more than 50% thanks to his leadership in expanding the company's R&D brain trust and completing an FDA application for its latest rare disease treatment.

Alexion's cornerstone asset is Soliris, an antibody approved to treat the rare paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. And while Soliris--and its roughly $500,000 price tag--have garnered most of the headlines, Alexion's R&D group, under Mackay's stewardship, has made strides in expanding the company's portfolio of treatments.

The company's top R&D prospect is asfotase alfa, an enzyme-replacement therapy for the rare hypophosphatasia that is awaiting approval in the U.S. and Europe. And, through its $8.4 billion acquisition of Synageva, Alexion acquired sebelipase alfa, another synthesized enzyme awaiting approval for lysosomal acid lipase deficiency. Each treatment has received the FDA's coveted breakthrough-therapy designation.

Meanwhile, Mackay's team is at work on studies testing whether Soliris can treat refractory myasthenia gravis, relapsing neuromyelitis optica, delayed graft function and antibody mediated rejection. And behind its lead drug, Alexion is developing early-stage therapies aimed at the same target, plus Phase I treatments for rare metabolic diseases and preclinical candidates in the mRNA field.

- here's the proxy

For more:
Special Report: Science pays: 2013's 10 best-compensated R&D chiefs in biopharma - Martin Mackay
Rare-disease powerhouse Alexion grabs an option on muscular dystrophy buyout
Alexion bags another FDA 'breakthrough' for rare-disease drug
Booming Alexion looks to Ensemble platform for ultrarare disease programs
Alexion snags latest 'breakthrough' coup with PhIII rare-disease drug

Martin Mackay, Alexion Pharmaceuticals
Read more on

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.